The Far Right Is Becoming Obsessed With Race and IQ
By Ali Breland,
The Atlantic
| 08. 20. 2024
“Joining us now is Steve Sailer, who I find to be incredibly interesting, and one of the most talented noticers,” Charlie Kirk said on his internet show in October. Kirk, the 30-year-old founder of Turning Point USA, a right-wing youth organization, slowed down as he said “noticers,” looked up at the camera, and coyly flicked his eyebrows.
That term—noticer—has become a thinly veiled shorthand within segments of the right to refer to someone who subscribes to “race science” or “race realism,” the belief that racial inequities are biological. In his interview with Kirk, Sailer noticed that “Blacks tend to commit murder about 10 times as often per capita as whites, and it’s not just all explained by poverty.” Sailer, one of the most prominent peddlers of race science in the United States, has made a career out of noticing things. (Last year, he published an anthology of his writing titled Noticing.) He has claimed that Black people tend to have lower IQs than white people (while Asians and Ashkenazi Jews tend to have higher IQs). Sailer...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...